Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Deals

Innovent Biologics and JD Health Form Strategic Partnership to Enhance Drug Supply and Healthcare Services

Fineline Cube Jul 15, 2025

China-based Innovent Biologics Inc., (HKG: 1801) and JD Health International Inc., (HKG: 6618) have officially...

Company Drug

Shanghai Henlius Biotech Initiates US Patient Dosing in Phase III Trial for HER2-Positive Gastric Cancer

Fineline Cube Jul 15, 2025

China-based Shanghai Henlius Biotech Inc., (HKG: 2696) announced the first patient dosing in the US...

Company Drug

Bayer AG’s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction ≥40%

Fineline Cube Jul 15, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from...

Company Drug

Sichuan Biokin’s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma

Fineline Cube Jul 15, 2025

China’s Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...

Company Deals

Hunan Mabgeek Biotech Files for Hong Kong IPO to Expand Innovative Biologics Pipeline

Fineline Cube Jul 15, 2025

China-based Hunan Mabgeek Biotech Co., Ltd has submitted an application to the Hong Kong Stock...

Company Drug

GSK’s Arexvy RSV Vaccine Expansion for Adults 18-49 Receives FDA Review

Fineline Cube Jul 15, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has...

Others

Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment

Fineline Cube Jul 14, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name:...

Company Drug

Boao Super Hospital Introduces Xiaflex for Non-Surgical Peyronie’s Disease Treatment

Fineline Cube Jul 14, 2025

Boao Super Hospital in Hainan last week successfully introduced Xiaflex (collagenase clostridium histolyticum), a nonsurgical...

Company Deals

Lexenpharm Partners with AptarGroup for Single-Dose Nasal Spray Services in Greater China

Fineline Cube Jul 14, 2025

China-based Lexenpharm late last week announced a strategic partnership with Aptar Pharma, a US-based global...

Company Deals Drug

Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development

Fineline Cube Jul 14, 2025

US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ:...

Company Deals

Royal Philips and Suzhou Peixin Collaborate on AI-Powered Interventional Therapy Platform for Structural Heart Disease

Fineline Cube Jul 14, 2025

Dutch device giant Royal Philips (NYSE: PHG) and China-based Suzhou Peixin Technology Co., Ltd. late...

Company Drug

YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study

Fineline Cube Jul 14, 2025

Shanghai-based YolTech Therapeutics announced that it has received clearance from the National Medical Products Administration...

Company Legal / IP

CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings

Fineline Cube Jul 14, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings...

Others

Eisai Announces Commercial Release of Urece (Dotinurad) from Suzhou Facility in China

Fineline Cube Jul 14, 2025

Japan-based Eisai (TYO: 4523) announced the official commercial release of the first batch of its...

Company Drug

InnoCare Pharma Receives FDA Approval for Mesutoclax in Myeloid Malignancies

Fineline Cube Jul 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical trial...

Company Drug

Pfizer and Astellas’ Xtandi Shows Positive Results in Phase III EMBARK Study for Prostate Cancer

Fineline Cube Jul 14, 2025

Partners Pfizer (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced positive topline results from...

Company Drug

Bayer’s Elinzanetant Granted UK Marketing Authorization for Menopause-Related Vasomotor Symptoms

Fineline Cube Jul 11, 2025

Germany’s Bayer (ETR: BAYN) this week announced that the UK Medicines and Healthcare products Regulatory...

Company Deals Drug

AbbVie Licenses IGI Therapeutics’ ISB 2001 for Oncology and Autoimmune Diseases

Fineline Cube Jul 11, 2025

US-based AbbVie (NYSE: ABBV) this week announced a licensing agreement with IGI Therapeutics SA, a...

Company Drug

Jiangsu Jibeier Receives NMPA Approval for Clinical Trials of JJH201601 Liposome in Advanced HNSCC

Fineline Cube Jul 11, 2025

China-based Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566) announced that it has received clinical approval...

Company Drug

Fosun Pharmaceutical Launches Phase III Study for Fumaining in Pediatric Low-Grade Glioma

Fineline Cube Jul 11, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the initiation of a...

Posts pagination

1 … 123 124 125 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.